Stephen T. Keir

发表

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

S. Keir, P. Houghton, C. Morton, 2012, Pediatric blood & cancer.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

A novel low‐molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

Osamu Ohmori, S. Keir, D. Bigner, 2007, Molecular carcinogenesis.

Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Initial testing (stage 1) of the multi‐targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas

I. Pastan, S. Keir, D. Bigner, 2011, International journal of cancer.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

S. Keir, J. Maris, O. Hampton, 2015, Pediatric blood & cancer.

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of topotecan by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Initial testing of lenalidomide by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer

S. Keir, D. Bigner, L. Jones, 2007, Psycho-oncology.

Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.